Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADXN 
Addex Therapeutics Ltd (ADXN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: ADXN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.5% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.61M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta 1.99 | 52 Weeks Range 6.51 - 13.27 | Updated Date 08/13/2025 |
52 Weeks Range 6.51 - 13.27 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3521.74% | Operating Margin (TTM) -853.23% |
Management Effectiveness
Return on Assets (TTM) -25.09% | Return on Equity (TTM) -163.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4993633 | Price to Sales(TTM) 34.97 |
Enterprise Value 4993633 | Price to Sales(TTM) 34.97 | ||
Enterprise Value to Revenue 23.64 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 1069140 | Shares Floating 26107116 |
Shares Outstanding 1069140 | Shares Floating 26107116 | ||
Percent Insiders - | Percent Institutions 1.13 |
Upturn AI SWOT
Addex Therapeutics Ltd
Company Overview
History and Background
Addex Therapeutics Ltd (ADXN) is a pharmaceutical company pioneering allosteric modulation-based drug discovery and development. Founded in 2002 in Geneva, Switzerland, it initially focused on research partnerships. Over time, it has transitioned towards developing its own pipeline of novel small molecule allosteric modulators for neurological disorders and other diseases. Significant milestones include progressing lead compounds through clinical trials and securing strategic collaborations.
Core Business Areas
- Neurology: Focuses on developing treatments for neurological disorders, including Parkinson's disease and other movement disorders.
- Allosteric Modulator Platform: Leverages its proprietary platform to discover and develop novel allosteric modulators targeting GPCRs and other receptors.
Leadership and Structure
The leadership team comprises experienced professionals in drug discovery, clinical development, and business management. The company operates with a matrix structure, organizing teams around specific therapeutic programs and functional areas.
Top Products and Market Share
Key Offerings
- Dipraglurant (ADX71149): A negative allosteric modulator of the mGluR5 receptor being developed for treatment of dyskinesia associated with Parkinson's disease. Market share data is currently in clinical trial phase, therefore, there is no current market share. Competitors include other companies developing treatments for Parkinson's related movement disorders.
- ADX88178: A positive allosteric modulator of GABA-B receptor being developed for treatment of Schizophrenia. This is also in clinical trials. Competitors include existing antipsychotic medications and companies developing novel treatments for Schizophrenia.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with significant investment in drug discovery and clinical development. Growth is driven by unmet medical needs, aging populations, and technological advancements. Increasing regulatory scrutiny and pricing pressures pose challenges.
Positioning
Addex Therapeutics Ltd positions itself as a leader in allosteric modulation, offering a differentiated approach to drug discovery. Its competitive advantage lies in its proprietary platform and expertise in developing novel small molecule modulators.
Total Addressable Market (TAM)
The total addressable market (TAM) for Addex's target indications (e.g., Parkinson's disease dyskinesia, Schizophrenia) is substantial, potentially exceeding tens of billions of dollars. Addex's positioning is focused on addressing unmet needs within these markets using its novel allosteric modulation approach.
Upturn SWOT Analysis
Strengths
- Proprietary allosteric modulator platform
- Experienced management team
- Promising clinical pipeline
- Strategic partnerships
Weaknesses
- Limited financial resources
- High R&D costs
- Regulatory approval risks
- Dependence on strategic partnerships
Opportunities
- Expanding clinical pipeline
- Out-licensing or partnering programs
- Entering new therapeutic areas
- Capitalizing on growing market for neurological disorders
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Pricing pressures
Competitors and Market Share
Key Competitors
- ABBV
- TEVA
- LLY
- VRTX
Competitive Landscape
Addex faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its innovative allosteric modulation platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are dependent on pipeline progress and partnership achievements.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization efforts.
Recent Initiatives: Recent initiatives include advancing lead compounds through clinical trials, securing strategic collaborations, and expanding the intellectual property portfolio.
Summary
Addex Therapeutics is a developing pharmaceutical company pioneering allosteric modulation. Its platform and clinical pipeline offer potential, but its limited financial resources and dependence on partnerships are risk factors. Successfully advancing its lead compounds through clinical trials is critical for future growth. The company faces competition from larger, well-established pharmaceutical firms and needs to overcome significant regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-Party Market Research Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on publicly available information and estimates, and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Addex Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-01-29 | Co-Founder, CEO & Director Mr. Timothy Mark Dyer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | |
Full time employees 2 | |||
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.